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Abstract
The rise in antibiotic resistance has led to an increased research focus on discovery of new antibacterial candidates. While
broad-spectrum antibiotics are widely pursued, there is evidence that resistance arises in part from the wide spread use of
these antibiotics. Our group has developed a system to produce protein affinity agents, called synbodies, which have high
affinity and specificity for their target. In this report, we describe the adaptation of this system to produce new antibacterial
candidates towards a target bacterium. The system functions by screening target bacteria against an array of 10,000 random
sequence peptides and, using a combination of membrane labeling and intracellular dyes, we identified peptides with
target specific binding or killing functions. Binding and lytic peptides were identified in this manner and in vitro tests
confirmed the activity of the lead peptides. A peptide with antibacterial activity was linked to a peptide specifically binding
Staphylococcus aureus to create a synbody with increased antibacterial activity. Subsequent tests showed that this peptide
could block S. aureus induced killing of HEK293 cells in a co-culture experiment. These results demonstrate the feasibility of
using the synbody system to discover new antibacterial candidate agents.
Citation: Domenyuk V, Loskutov A, Johnston SA, Diehnelt CW (2013) A Technology for Developing Synbodies with Antibacterial Activity. PLoS ONE 8(1): e54162.
doi:10.1371/journal.pone.0054162
Editor: Tarek Msadek, Institut Pasteur, France
Received March 20, 2012; Accepted December 10, 2012; Published January 23, 2013
Copyright:  2013 Domenyuk et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant from DARPA (http://www.darpa.mil/) under the 7 Day Biodefense Program to SAJ (grant number W911NF-10-1-
0299). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors declare competing financial interests with two provisional patents 11-1392-PRO and 11-739-PRO. This does not alter the
authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: chris.diehnelt@asu.edu
Introduction
While there is no perfect understanding of the forces directing
evolution of antibiotic resistance a prominent view holds that these
issues are in part the consequence of the widespread use of broad
spectrum antibiotics [1,2]. It has been proposed that next
generation antimicrobial treatments must focus on: developing
pathogen-specific antibiotics, greatly improving diagnostics, and
expanding the role of immunotherapy [3]. Along these lines, there
has been a resurgence of monoclonal antibody (mAbs) based
therapeutic development [4,5]. Historically, antibody therapies
were the first effective anti-infective agents (e.g. for pneumonia,
meningitis, erysipelas). However, their wide usage is restricted by
the high cost of development and production of pathogen specific
mAbs and the large number of current antimicrobial drugs on the
market. Other groups are developing antimicrobial peptides (APs)
as a means of avoiding resistance, as there have been few reports of
resistance arising to APs [6]. Despite numerous attempts to
develop new AP-based therapeutics using either natural [7,8],
optimized via amino acid substitutions [9–12] or dimeric peptides
[13,14], only a few products have reached the market [15]. APs
have two limitations. One is that there are relatively few for
development [16] (131 APs for Gram-negative bacteria and 283
for Gram-positive peptides in Antimicrobial Peptide Database,
February 2012). The second is that they generally have high
toxicity and broad activity, which is consistent with their
evolutionary origin [17].
Our group has previously developed a class of affinity agents
called synbodies that are produced by screening the target of
interest against a peptide microarray to discover low affinity
peptides that are then joined on a scaffold to produce high affinity,
highly specific binding agents [18–20]. Synbodies can be easily
modified to increase affinity [20,21], have an orthogonal
functional group that can be used for conjugation to a wide
variety of moieties, and should be ideal lead therapeutic
candidates. We sought to extend this platform to bacteria in an
attempt to create synbodies with specificity towards a target
pathogen that can function as new antibacterial candidates. By
targeting the bacterial surface, we should reduce the likelihood of
the target bacteria developing resistance.
The discovery platform is similar to the platform we have used
to develop synbodies to protein targets but with a few important
modifications: 1) whole bacteria are screened against the 10,000
random-sequence peptides microarray; 2) pathogen specific
peptides with binding or lytic action are identified from a
microarray functional screening assay and 3) combining binding
and lytic peptides produces synbodies with activity against a
particular pathogen (Figure 1A). By screening whole bacteria, we
have the ability to profile any possible pathogen without selecting
specific surface components, such as lipoteichoic acids, proteins
and peptidoglycans for Gram-positive bacteria or lipopolysaccha-
rides (LPS) for Gram-negative bacteria. The microarray based
functional assay distinguishes between peptides with antimicrobial
activity and those that bind without affecting growth providing a
large source of pathogen specific peptides that can be identified in
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a rapid manner. We hypothesize that this technology for
developing specific antibiotics to any pathogen will provide a
straightforward method for designing new compounds. As a test of
this system, we developed a synbody against Staphylococcus aureus
(SA), the Gram-positive bacteria that is one of the causative agents
of hospital acquired bacterial pneumonia [22] to demonstrate a
general method to create new antibacterial candidates.
Results
Bacterial Cell Binding to Peptide Microarrays
The basic elements of the synbody process are shown in
Figure 1A. In the first step, labeled bacteria are applied to the
peptide microarray, which consists of 10,000 peptides of 20aa
length. The composition of each peptide is known, but generated
by a random number generator using 19 aa (cysteine was omitted).
We found that the (3-aminopropyl)triethoxysilane (APTES)
microarray surface chemistry used in earlier published reports of
screening proteins, antibodies and carbohydrates [18,23–25]
showed high levels of non-specific binding to the interstitial
regions of the array and low level binding to peptide spots when
whole bacterial cells were screened. To address these issues we
developed an alternative microarray surface chemistry using a
hyperbranched polymer that reduced non-specific binding and
increased the peptide density (Figure S1). We chose a diverse set of
bacteria to test the general applicability of this approach and
screened Gram-negative bacteria, Escherichia coli O111:B4 (EC)
and Pseudomonas aeruginosa (PA); and Gram-positive bacteria,
Streptococcus mutans (SM), Staphylococcus aureus (SA) and Bacillus
subtilis (BS) against the 10,000 peptide library. In order to identify
peptides that bound to the bacteria surface but did not affect the
function of the bacterial membrane, we used Cell Tracker Orange
(CTO), an internalizing dye that is activated upon entering
bacterial cells and remains inside intact cells. Each bacterium was
labeled with CTO and screened against the peptide microarray
with each experiment performed in duplicate at with four
technical replicates per peptide sequence. The raw images
represent the same area of five peptide microarrays processed
with different bacterial species (Figure 1B), which bind in a clearly
distinguished pattern. A competition experiment was also
performed in which the CTO labeled bacterium was screened in
the presence of 206 excess of un-labeled bacteria to confirm the
bacterial cell binding. Construction of scatter plots [25,26] for
both datasets (binding and competition) (Figure 2A) reveal
peptides with signals that are at least twofold higher than those
in the presence of excess un-labeled bacteria (black filled circles in
Figure 2A). Whole bacterial cell binding can clearly be seen in
Figure 2B, where EC binding to selected peptides (highlighted in
Figure 2A) was visualized by fluorescent microscopy. This assay is
a straightforward method to identify peptides that specifically bind
a pathogen and works well for both Gram-negative and Gram-
positive bacteria (Figure 2A,C).
Figure 1. Bacteria binding to peptide microarrays. (A) Workflow to develop pathogen specific antibiotics. Bacterial cells are applied to the
peptide microarray carrying dyes either in cytoplasm or on the membrane. Intracellular dye Cell Tracker Orange (CTO) identifies peptides that bind
bacterial cells without disrupting the cell membrane while the outer membrane label Alexa Fluor 555 identifies either intact or dead cells. Comparing
the profiles of a pathogen at the same peptide sequence enables the selection of peptides with binding or lytic activity. After in vitro validation,
linking together a peptide with antimicrobial activity and a specific binder for the pathogen produces a synbody. (B) Distinct profiles of CTO stained
E.coli O111:B4 (EC), P. aeruginosa (PA), S. aureus (SA), S. mutans (SM), B. subtilis (BS) on representative sub-array (48 peptides from 10,000 total). Cell
binding signals are depicted as a false color (green).
doi:10.1371/journal.pone.0054162.g001
Developing Antibacterial Synbodies
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e54162
Identification of Antimicrobial Peptides on a Peptide
Microarray
While this technique works well to select peptides that
specifically bind surface components on the target bacteria, these
peptides might not have intrinsic antibacterial activity. As depicted
in Figure 1, this concept of the synbody involves combining a high
specificity binding peptide with a peptide that has high antibac-
terial activity, such as a naturally occurring antimicrobial peptide.
However, many naturally occurring APs function by disruption of
the bacterial membrane and have been evolutionarily optimized to
have broad activity and can be quite toxic [17]. We hypothesized
that we could use the peptide microarray to identify both binding
peptides and lytic peptides. To do so we used an N-hydro-
xysuccinimide (NHS) ester activated dye, AlexaFluor-555 (AF) to
label the primary amines present in the bacterial membrane.
Peptides that bind but do not disrupt the bacterial membrane
should have signal when detected with both CTO and AF
(CTO+AF+) while peptides with lytic activity cause CTO to leak
out of cells once the membrane is disrupted (CTO-AF+). The
binding/competition assay was performed with SA labeled with
both dyes and peptides that showed binding to SA-CTO (black
circles) were inspected on the scatter plot with AF data (Figure 3A).
Most of the peptides repeated in the AF data can be considered as
binder-candidates (CTO+AF+). However, there are additional
peptides (red circles) in this area that may also have lytic activity
(CTO-AF+). Examples of functional assay performance with other
bacteria EC, PA, BS, SM can be seen in Supplementary Figure
S2. Examples of microarray profiles of CTO and AF labeled
bacteria for four different peptides show that the profile of binding
peptides and lytic peptides can be clearly distinguished (Figure 3B).
We then analyzed this data to determine the specificity of binding
and lytic peptides across the five bacteria tested. Using a linear
classifier, we were able to identify specific binding (Figure 3C) as
well as lytic (Figure 3D) peptide-candidates for SA.
Figure 2. Demonstration of bacteria binding to peptide microarrays. (A) Binding data of CTO stained EC (x axes) plotted vs negative control
(y axes). Both axes show raw median fluorescent signal at 543 nm on a logarithmic scale. Green lines delimit the twofold change. Dark dots outside of
two-fold change are binder-candidates. (B) EC binding to peptides annotated in (A) on custom polymer microarray detected by fluorescent
microscopy. Upper left image is negative control (non-binding peptide EFSN). Scale – 100 mm. (C) Binding and competition dataset for SM and SA.
Annotated dark dots are peptide-binders for EC selected in (A) and demonstrate binding specificity.
doi:10.1371/journal.pone.0054162.g002
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Validation of in vitro Activity of Microarray Selected
Peptides
We then tested the correlation between peptides with micro-
array predicted activity and their ability to inhibit bacterial growth
in vitro. Based on their microarray profile, we chose 40 peptides
that were identified as binding peptides, lytic peptides, or non-
binding peptides for EC, PA, SA, SM, and BS and tested each
peptide in a standard bacterial growth inhibition assay. In this
manner, we could assess the performance of the selection process.
Peptides were screened at 100 mM (Figure 4A) and the number of
peptides that inhibited bacterial growth greater than 50% is shown
in Table 1 along with the average inhibition of each group. As can
be seen, more than 50% of peptides that were predicted to have
lytic activity from the microarray assay had inhibitory activity in
vitro and those peptides showed stronger growth inhibition
compared to either peptide binders or non-binding peptides.
The correlation between inhibitory activity of immobilized
peptides and their behavior in solution was quite good considering
that the density of peptide immobilized on a microarray is quite
high. It is possible that the high avidity of the peptide on the
microarray causes some peptides to have a lytic phenotype when
immobilized but not have activity when free in solution. We next
determined the minimum inhibitory concentration (MIC) for a
subset of peptides that showed growth inhibition (Table S1). From
these data, it can be seen that a number of peptides showed broad
bacterial inhibition while other peptides had little to no activity.
Microarray predicted properties of peptides were additionally
confirmed by growing bacterial cultures on the plates after mixing
with lytic or binding peptides (Figure 4B). Peptides that were
predicted to be lytic from the microarray screen inhibited bacteria
growth while binding peptides did not. Based on these results, the
microarray screen does select peptides with antibacterial activity.
Evaluation of a S. aureus Synbody
To develop a S. aureus synbody, we combined a peptide with
activity against SA and a SA specific binding peptide (Figure 5A)
similar to the approach described in [27,28]. Peptide
RWRRHKHFKRPHRKHKRGSC (peptide RW) was selected
Figure 3. Selection of binding and lytic peptides from microarray screening. (A) Scatter plots comparing binding/competition data for SA
with intracellular stain CTO (left) and membrane label AF (right). Both axes show raw median fluorescent signal at 543 nm on a logarithmic scale.
Green lines delimit the twofold change. Peptide-binders (dark dots) are selected out of twofold change on x axes as those where CTO-cells were
competed with excess of non-stained cells and repeated with AF labeled cells. Other peptides out of twofold change on x axes at SA-AF (red dots) are
considered lytic as they were not detected with CTO. (B) Microarray binding of CTO stained vs AF labeled EC, PA, SA, SM and BS for peptides HWK,
RWR, DRI, HPW (spotted in duplicate). L = lytic peptide (CTO-AF+). B = binding peptide (CTO+AF+). N =no binding. (C) Specificity and uniqueness of
bacterial profiles at peptide microarray in binding peptides dataset (D) and for lytic peptides dataset. SA data presented in Venn diagrams have had
SM and BS binding peptides filtered out.
doi:10.1371/journal.pone.0054162.g003
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for its activity for SA and PA, while peptide DRIFHKMQHK-
PYKIKKRGSC (peptide DR) was selected for its high binding to
SA on the peptide microarray. This synbody had two times higher
antibacterial activity for SA than the original lytic peptide yet did
not inhibit growth of E. coli or S. mutans (Table 2). This was not
observed for P. aeruginosa where the MIC of the synbody is roughly
the same as that of the lytic peptide. While the synbody had
activity against B. subtilis, this bacterium was the most susceptible
to growth inhibition by individual peptides (Table S1). We also
tested the antibacterial activity against three species of bacteria
that were not included in the selection process: the closely related
commensal bacteria Staphylococcus epidermidis; and two other Gram-
negative bacteria, Escherichia coli O157:B7 and Burkholderia
thailandensis. It was found (Figure S3) that the synbody inhibited
the growth of S. epidermidis (MIC=1.75 mM) and E. coli O157:B7
(MIC=14 mM) while it did not inhibit the growth of B.
thailandensis, which is resistant to many antibacterial peptides
[29]. Analysis of bacterial growth kinetics (Figure 5B) illustrates the
advantage of the synbody over the original peptides at 25 mM
concentration of each. Noticeable growth of S. aureus in the
presence of the peptide RW was detected after 4 hours incubation,
while in the presence of synbody noticeable growth was detected
only after 16 hours. Interestingly, a mixture (not conjugate) of the
two original peptides RW and DR also shows improved activity,
with bacterial growth suppressed for 9 hours. However, a mixture
of peptides is still less effective than the synbody.
Figure 4. Validation of microarray predicted lytic activities of peptides. (A) Relative growth inhibition of EC, PA, SA, SM and BS by peptides
HWK, RWR, DRI, HPW, HKH at 100 mM. End-point measurement after 18 h. ‘‘+ C’’ - positive control kanamycin, 100 mM. L – microarray predicted lytic
activity of peptide B – binding activity of peptide. N – no microarray profile. The error bars are standard deviations of triplicate measurements. (B)
Cultures were plated after 5 minute incubation with 100 mM of binding or lytic peptides. Pictures were taken after 24 hours growth. Upper plate is
negative control for each strain. Peptide-binders: DRI for SA; KQK for BS. Lytic peptides: RWR for SA; HRK for BS.
doi:10.1371/journal.pone.0054162.g004
Table 1. Summary of in vitro growth inhibition screening of microarray selected peptides.
Actual versus Predicted Inhibition Average Inhibition
Bacteria Peptide Binders Lytic Peptides Non-Binders Peptide Binders Lytic Peptides Non-Binders
E. coli 0/11 5/11 1/11 0% 76% 50%
P. aeruginosa 0/17 6/14 0/7 0 82% 0%
S. aureus 0/8 6/8 0/22 0% 84% 0%
S. mutans 4/22 8/12 0/4 41% 68% 0%
B. subtilis 0/4 13/15 3/19 0% 80% 77%
doi:10.1371/journal.pone.0054162.t001
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The lytic activity of the synbody and the peptide RW was tested
by adding each to a S. aureus culture at ,1/3 of log phase at
,1.76109 CFU/ml (Figure 5C). The growth of S. aureus in the
presence of the peptide plateaus while bacteria treated with
synbody shows a gradual reduction in OD after synbody addition.
This suggests a bacteriostatic rather than bactericidal effect of the
synbody given that the synbody was added at a concentration that
was 7 times the MIC. To further clarify this effect, we performed a
kill curve kinetic study of the synbody and each peptide (Table S2).
As can be seen, kanamycin has a rapid bactericidal effect (.3 log10
reduction in CFU/mL) when added at 2 times and 4 times the
MIC. However, neither the synbody nor the individual peptides
had a bactericidal effect at 4 times the MIC. Thus, we conclude
that the synbody has a bacteriostatic rather than a bactericidal
effect on S. aureus.
The Synbody Inhibits S. aureus Induced Cell Death
To ensure that the synbody was not highly toxic like many
antimicrobial peptides, we tested the synbody for toxicity against
mammalian cells using a standard hemolytic assay against murine
red blood cells (Figure 6A) and a growth inhibition assay against
human kidney cells (HEK293) (Figure 6B). It was found that the
Figure 5. In vitro characterization of S. aureus synbody. (A) Structure of S. aureus synbody. (B) Bacterial growth of S. aureus over time after
treatment with peptides or synbody. Measurements were taken hourly. Data points represent the average of three independent experiments.
Starting S. aureus concentration is ,26105 CFU/mL. (C) Test of lytic activity of lytic peptide and synbody. S. aureus was grown until ,1.76109 CFU/
mL and the peptide or synbody was added to the final concentration of 100 mM at time zero. Data points represent the average of three independent
experiments.
doi:10.1371/journal.pone.0054162.g005
Table 2. MIC values of S. aureus binding peptide, inhibitory peptide, and synbody.
Gram-positive Bacteria Gram-Negative Bacteria
S. aureus S. mutans B. subtilis E. coli O111:B4 P. aeruginosa
DRIFHKMQHKPYKIKKRGSC N.I. N.I. N.I. N.I. N.I.
RWRRHKHFKRPHRKHKRGSC 2861.5 mM N.I. N.I. N.I. 2762.3 mM
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synbody did not lyse mouse red blood cells or inhibit the growth of
HEK293 cells. These data demonstrate that we can combine a
peptide with rather broad growth inhibition activity with a peptide
that specifically binds S. aureus to produce a synbody without a
widespread toxic effect.
After this preliminary toxicity test, we wished to determine if the
synbody could protect mammalian cells from bacterial induced
cell death. We used a model system where human embryonic
kidney cells (HEK293) were co-cultured with S. aureus to simulate
S. aureus infection of kidney cells in transplants [30]. Cell viability
was determined by cellular ATP content and was normalized to
100% for the cells alone control. We tested a range of conditions at
which S. aureus can grow in tissue culture media and found that
there was significant decline in HEK293 viability with as little as
1.256103 CFU/ml of S. aureus. The final experimental setup
consisted of 1.256106 CFU/ml of SA (10006 higher than
minimal harmful concentration of bacteria) added alone or with
synbody or the individual peptides added to at 25 mM. A 180 mM
solution of PenStrep was used as a positive control and provided
complete protection in this assay. Treatment with the individual
peptides offered no protection from S. aureus induced cell death
while the synbody treated cells maintained about 70% cell viability
(Figure 6C). The protective effect of the synbody on human cells
was confirmed using light microscopy after 24 hours of treatment
(Figure 6D). Large colonies of S. aureus and dead cells are clearly
seen in the untreated image while the synbody treated sample has
few colonies of S. aureus present. These results demonstrate that the
synbody has a protective effect against a simulated S. aureus
infection.
Discussion
Here we demonstrate a simple and general method for
screening bacteria on peptide microarrays. We have shown that
a variety of bacteria can be panned and simultaneously screened
for peptides that bind the bacteria or lyse them, using a two dye
system. When these peptides are resynthesized and tested in
solution, over half manifest the phenotype selected on the array.
When a SA specific binding peptide was combined in one synbody
with a broadly lytic peptide, the specificity and activity was
improved. This improved synbody was relatively non-toxic on
mammalian cells in culture. Finally, we show that the synbody is
also effective in an in vitro assay for protecting human cells against
S. aureus.
The rise of multiple sources of antibiotic resistance creates
urgency not only in the development of new antibiotics but on the
development of new systems of producing antibiotic candidates.
Figure 6. Testing of synbody toxicity and demonstration of a protective effect on human cells in co-culture with S. aureus. (A)
Hemolytic activity of SA synbody and individual peptides on mouse red blood cells. (B) Test of synbody cytotoxicity for HEK293 cells versus original
peptides. The synbody was added to cells for 48 hours and cell viability was measured by BrdU proliferation assay. (C) Viability of HEK293 cells in co-
culture with S. aureus with and without synbody treatment, as measured by cellular ATP content measurement. Data are normalized to the cellular
ATP content of cells only. Synbody (25 mM), peptide (25 mM) or antibiotic control (180 mM) was added to co-culture immediately after mixing. The
error bars represent the standard deviation of triplicate measurements. (D) Light microscopy (106) of cells only, cells in co-culture with S. aureus for
24 hours, cells treated with 25 mM RW peptide and cells treated with 25 mM synbody.
doi:10.1371/journal.pone.0054162.g006
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We are focusing on technologies to create species specific
antibiotics that would be difficult to develop resistance to. Ideally,
this technology could be applied in a systematic method that is
both rapid and cost effective. In this work, we have demonstrated
the feasibility of such a system to quickly develop an antimicrobial
synbody that has a relatively narrow specificity for Staphylococcus
aureus.
While others have detected antimicrobial activity on cellulose-
tethered peptides using bacteria transformed with luciferase gene
[31,32] our method offers several advantages over this method: (i)
the functional assay allows detection of lytic peptides as well as
peptide-binders directly on microarrays; (ii) the small peptide
library was characterized prior to spotting, in contrast to peptides
synthesized directly on the cellulose support which are not
characterized prior to use; (iii) the hyperbranched polymer surface
has higher sensitivity than other surfaces; and finally, (iv) bacteria
can be profiled in as little as 2 hours. The unique combination of
bacterial profiling on a microarray with subsequent selection of
binding versus lytic peptides enables a very straightforward process
for selection of pathogen specific candidates. The technology for
designing a synbody based on a pathogen’s microarray profile that
combines two or more peptide characteristics is fundamentally
new to the antimicrobial field. The flexibility of the platform
suggests that it would be possible to use this system to develop
antibacterial candidates to almost any pathogen in a rapid
manner. It should also be possible to improve the activity and
possibly specificity of the synbody for a target bacterium. As has
been demonstrated with proteins [18,20] combining two or more
peptides can produce synbodies with much higher affinity. A
simple mutagenesis protocol to improve peptide features for
binding proteins has also been presented [21] which may also be
applicable to bacteria. While peptide therapeutics have issues with
in vivo stability and pharmacokinetics, there are numerous
advances that have been made in the stabilization of peptide
therapeutics, that make the synbody approach a viable source of
new antibacterial candidates.
Materials and Methods
Animal experiments were conducted following an animal use
protocol (1099R) which was reviewed and approved by the
Arizona State University Institutional Animal Care and Use
Committee. Human tissue culture experiments were approved by
Arizona State University Institutional Review Board (Protocol #
0508000152).
Microarray peptides were synthesized by Alta Biosciences Ltd.
(Birmingham, UK). Lead peptides were synthesized in-house or by
Sigma Aldrich by using Fmoc chemistry and purified to 95% by
HPLC. Spectrophotometric measurements were carried out by
using a NanoDropH ND-1000, SpectraMax 190 and M5
(Molecular Devices). Microarrays were scanned with ProScanAr-
ray HT microarray scanner (Perkin Elmer).
Bacteria
Escherichia coli O111:B4 (ATCC) was grown at 37uC in Difco
nutrient broth medium for non-fastidious organisms (Becton,
Dickinson and Company 231000). Bacillus subtilis 1A423, Pseudo-
monas aeruginosa PAO-1 and Staphylococcus aureus UAB637 (kindly
provided by Center for Infectious Diseases and Vaccinology
(CIDV), the Biodesign Institute at Arizona State University (ASU))
were grown at 37uC in Luria-Bertani broth medium (LB, Fisher)
under aerobic conditions. Streptococcus mutans UAB147 Serotype C
(kindly provided by CIDV, ASU) and Streptococcus pneumoniae were
grown at 37uC in Todd-Hewitt (TH, Fisher) broth medium with
5% horse blood under anaerobic conditions. Escherichia coli
O157:H7 (ATCC) and Burkholderia thailandensis (ATCC) were
cultured in Mueller-Hinton broth medium (MH, Fisher) while
Staphylococcus epidermidis was cultured in TH broth medium.
Peptide Microarray Preparation
Prior to spotting of the peptide library, polymer slides were
prepared by: 1) Cleaning glass slides with Piranha solution (70:30
v/v mixture of concentrated H2SO4 and 30% H2O2. WARNING:
Piranha solution should be handled with caution and can detonate
if mixed with significant quantities of oxidizable organic materials)
for at least 1 hour at low rotation, followed by rinsing with H2O
and drying. 2) Slides were silanized in 1% solution of 3-
glycidoxypropyl-trimethoxysilane in anhydrous toluene for
30 minutes at 40uC, and washed with toluene (3 times). 3) Slides
were cured for 40 minutes at 120uC. 4) Slides were coated with a
solution of 6 mg/mL polyethylenimine in 10% ethanol for 1 hour
at room temperature with agitation. 5) Slides were activated with
sulfo-SMCC (Pierce Biotechnology, Rockford, IL, USA; Cat#
22622) to create a maleimide-activated surface. 6) The peptide
library was then printed using a contact spotter on the activated
slides. The maleimide-activated surface reacts with the sulfhydryl
group on the peptide’s terminal cysteine to orient the peptides on
the surface.
Microarray Assays
Before probing, the slides were treated with 90% trifluoroacetic
acid (TFA) to remove non-immobilized peptides, blocking groups
and probable organic impurities followed by dimethylfuran
(DMF), ethanol and deionized water washing. Then, the slides
were placed in a humidified chamber and blocked for 1 hour at
room temperature with buffer [3% bovine serum albumin (BSA),
0.014% mercaptohexanol and 0.05% Tween-20 in 16Tris
buffered saline (TBS)].
Turbidity of overnight cultures was measured at OD600. The
CFU/mL value was calculated according to the McFarland
Equivalence Turbidity standard (Remel, R20421). Cell cultures
were diluted to 86108 and washed 2 times with 16 phosphate
buffered saline (PBS) buffer with 0.05% FBS (Fetal Bovine Serum,
Invitrogen 10091-130). CTO staining solution was prepared by
adding 500 mL of pre-warmed appropriate media with 10 mM
CTO to one tube of washed cells and incubated in foil wrapped
tube for 1 hour at 37uC at 250 rpm. Alexa Fluor 555 NHS ester
(Invitrogen A32755) labeling solution was prepared by adding the
500 mL of 16TBS/FBS with the content of one pre-packed dye
vial dissolved in 10 mL DMSO to washed cells. The sample was
incubated in a foil wrapped tube for 1 hour at room temperature
with agitation. After staining/labeling, cells were washed with
16TBS/FBS. The amount of dyes and incubation times vary for
different pathogens and needed to be found experimentally.
After blocking the slides were washed with 16TBS-T (1630
inversion in a Coplin jar) and water (3630 inversions in a Coplin
jar). The slides were then dried by centrifugation at 1500 rpm for
2 minutes. Agilent hybridization chambers were used to ensure the
interaction of the solution (108 labeled cells in 16TBS with 0.03%
SodimM azide, 3% BSA and 0.05% Tween 20 in total 450 mL)
with the microarrays. To subtract false positive non-specific signals
driven by dye binding, we conducted competitions with 206
excess of un-labeled cells. Each microarray assay was performed in
triplicate. The slides were incubated for 1 hour at 37uC in the
rotator (Agilent Technologies). Then slides were washed with
16TBS-T (3630 inversions in a Coplin jar) and water (3630
inversions in a Coplin jar); the solution was changed each time.
Developing Antibacterial Synbodies
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Finally, the slides were dried by centrifugation at 1500 rpms for
2 minutes and scanned.
Microarray scanning and data analysis
Microarrays were scanned by using a Perkin-Elmer ProSca-
nArray HT Microarray Scanner with the 488, 543 and 633 nm
excitation lasers at 100% power and 70% photomultiplier tube
gain. Detection was done at 570 nm for Cell Tracker Orange and
AF555, at 508 nm for SYTO 9 and at 670 nm for DRAQ5. All
scanned images were analyzed by using GenePix Pro 6.0 software
(Axon Instruments, Union City, CA, USA). Upon careful visual
inspection, bad spots were eliminated by flagging them absent.
Median spot intensities were used in further analyses. Image-
processed data were imported from GenePix for the following
statistical analysis of microarray data to GeneSpring 7.2 (Agilent,
Inc., Palo Alto, CA, USA). For correct analysis, each slide was
normalized either to 50th percentile or by subtracting the local
background from median intensity at each spot. Measurements of
less than 0.01 were set to 0.01. The microarray profiles collected
for each bacterial strain were compared by using scatter plots
[25,26]. Binding assay data were plotted versus competition assay
data for each dye separately. Peptides that demonstrated at least 2
times higher intensity in binding assay were considered for
subsequent analysis. Peptides with signals at both CTO and
AF555 dyes (CTO+AF+) were considered as binders. Lytic
peptides were selected as those with no signal in the CTO channel
and signal in the AF555 channel (CTO-AF+). In order to
distinguish specific peptide-binders and APs candidates the profiles
of different strains were compared by Venn diagrams.
Fluorescent Microscopy
For the microscopic detection of bacterial binding to the peptide
microarray we printed custom slides with 10–20 peptides of
interest. All procedures of microarray preparation and processing
were the same as described above. After the last wash, 50 mL of
16PBS was applied to the slides and spread under a cover slip.
Binding was evaluated using fluorescent microscopy (Olympus
BX61), at 660 magnification with immersion oil with Cy3
excitation laser. Digital images were collected using factory-
supplied software DP Controller 2.2.1.227 Olympus Corporation.
Synbody Synthesis
Bivalent synbody was synthesized via a modified divergent solid
phase peptide synthesis using Fmoc-Lys(ivDde)-OH as the scaffold
using the protocols outlined in [19]. Synthesis was performed by
removal of the Fmoc-protecting group followed by synthesis of
peptide 1 on a-amino group of Lysine through stepwise addition of
Fmoc amino acids. Upon completion of peptide 1 synthesis, the N-
terminal Fmoc group was substituted with Boc group prior to
deprotection of the Ne-(ivDde) protecting group. The stepwise
assembly of peptide 2 was then accomplished at Ne-lysine position
using stepwise addition of Fmoc-protected amino acids on the
peptide synthesizer. The final protected synbody was treated with
cleavage cocktail for 2 hours at room temperature and precipitat-
ed in cold diethyl ether. The solid was separated from diethyl ether
by centrifugation and the top phase decanted off and pellet re-
suspended with another addition of dry diethyl ether. The cooling
and centrifugation processes were done in triplicate, as the
construct was dried and dissolved in water for HPLC purification.
Finally, the synbody was purified by HPLC and quality was
analyzed by MALDI mass spectrometry.
Minimum Inhibitory Concentration (MIC) and Kill Curve
Kinetic Analysis
MIC determinations were conducted utilizing the broth
microdilution assay according to the Clinical and Laboratory
Standard [33] in Mueller-Hinton (MH; Fisher) broth medium at
3562uC for EC, BS, PA, SA; in MH II (cation adjusted) with 5%
horse blood for SM. CFU number controls and survivors control
in bactericidal kinetics were conducted in MH agar for EC, BS,
PA, SA; in MH II agar with 5% sheep blood for SM. For time kill
curve studies, aliquots from each sample-treated well were
removed at the indicated time point, diluted with 16 PBS, and
serial dilutions of each sample were plated on agar plates. The
plates were incubated overnight and bacterial colonies were
counted. The results reported are the average of two experiments.
Hemolytic assay
The protocol was adopted from Shin et al [34]. Female BALB/
C mice were obtained from Charles River and housed in barrier
isolation caging with food and water provided ad libitum. Mouse
blood samples were collected via submandibular venipuncture
using a 5.0 mm lancet (MEDIpoint, Inc., Mineola, NY) into
heparinized tubes. All animal experiments were conducted
following an animal use protocol (1099R) that was reviewed and
approved by the Arizona State University Institutional Animal
Care and Use Committee. Briefly, fresh mice erythrocytes were
rinsed three times with PBS, centrifuged for 15 minutes at 900 g
and resuspended in PBS. Samples (100 mL) of the suspension (4%
in PBS, v/v) were plated in 96-well microtiter plates, after which
100 mL of the appropriate concentration peptide dissolved in PBS
was added. Plates were incubated for 1 hour at 37uC and then
centrifuged at 1000 g for 5 minutes. Aliqots (100 mL) of the
supernatant were transferred to 96-well plates, where hemoglobin
release was monitored using a microplate reader (Molecular
Devices) by measuring the absorbance at 414 nm. Percent
hemolysis was calculated by the following formula: % hemolysi-
s = [(A414in the peptide solution – A414in PBS)/(A414in 0.1%
Triton-X 100 – A414in PBS)] 6100. Zero and 100% hemolysis
were determined in PBS and 0.1% Triton-X 100, respectively.
Cytotoxicity assay
HEK293 (Human Embryonic Kidney cells were purchased
from ATCC) (105/mL cells) were seeded in individual wells of a
microtitre plate and incubated for 24 hours at 37uC with 5%
carbon dioxide in EMEM supplemented with 10% fetal bovine
serum and Penicillin/Streptomycin. Cells were then challenged
with synbody or peptides from 0.05 to 100 mM for either 24 or
48 hours. Cell viability was measured spectrophotometrically
(450 nm) following the addition a peroxidase-conjugated anti-
BrdU antibody, subsequent TMB degradation by peroxidase and
stopping by acidic solution, as per the manufacturer’s recommen-
dations (Cell Proliferation ELISA, BrdU, Chemicon (Millipore)).
Human tissue culture experiments were approved by Arizona
State University Institutional Review Board.
Co-culture of human embryonic kidney cells (HEK293)
and S. aureus
Done accordingly to protocol [35] with modifications. Bacteria
were grown on Mueller-Hinton (MH; Fisher) broth medium at
37uC for overnight. The bacteria were then harvested by
centrifugation and the pellet suspended in Eagle Minimum
Essential Medium (EMEM) supplemented with 10% fetal bovine
serum without antibiotics. The bacterial density was adjusted to
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108 CFU/mL (stock). Serial dilutions of this concentration were
prepared for further experiments.
HEK293 cells were cultured in complete EMEM (Minimum
Essential Medium Eagle Media) supplemented with 10% fetal
bovine serum and Penicillin/Streptomycin for 2 days in 75 cm2
cell culture flasks (Greiner) at 37uC in humidified atmosphere
containing 5% CO2. For experiments, the cells were harvested
through trypsin-EDTA treatment, seeded into 96 well tissue
culture plates ‘‘Microtest’’ (Falcon) at concentration 46105 cells/
mL. After 24 hours, the culture medium was replaced by either
fresh EMEM without antibiotics (negative control) or S. aureus
dilutions. To make the test conditions for the Synbody more
restrictive, 10006 excess of minimal harmful concentration of S.
aureus (1.256106 CFU/mL) was chosen for the set up of the co-
culture system. Synbody and peptides RW and DR (25 mM) were
added at 1 minute after starting the co-culture. After 24 hours of
co-culture, the cell viability was determined visually and on the
basis of a luminescence ATP detection assay ‘‘ATPlite’’ (Perkin
Elmer). For the measurement of cellular ATP the cells were lysed
(50 mL of mammalian cells lysis solution to 100 mL of cell
suspension) for 5 minutes in an orbital shaker at 700 rpm. After
lysis, a 50 mL of substrate solution containing Luciferase/Luciferin
was added to react with released ATP. After 5 minutes incubation
in an orbital shaker at 700 rpm, the emitted light was measured
with a luminometer (Clarity, BioTek Instruments, Inc.). The ATP
standard sample provided in ATPlite kit was diluted and measured
to build a standard curve. Luminescence was converted to the
cellular ATP content (nM) using the standard curve. The cellular
viability under test conditions was expressed as percent of an
untreated control (HEK293 cells).
Supporting Information
Figure S1 Peptide microarray surface chemistry.
(TIF)
Figure S2 Efficacy of functional assay for distinguishing
of binding and lytic peptides directly on microarray.
AF555-NHS labeled EC, PA, BS, SM (x axis) plotted versus
themselves in competition with 206 excess of non-labeled cells (y
axis). Both axes show raw median fluorescent signal at 543 nm on
a logarithmic scale. Green lines delimit the twofold change.
Annotated dark dots are peptide-binders detected previously with
CTO for each strain specifically. Peptides are classified ‘‘Binders’’
if repeated with AF (CTO+AF+) out of twofold compared to
negative control. Other peptides in this area (red dots) have profile
‘‘CTO-AF+’’ and classified ‘‘Lytic’’. Annotated peptides (black
filled circles) within 2-fold change were ignored as CTO false
positive signals. Note that some overlap in properties binder/lytic
is possible when signal ratio AF/CTO is exceeding 1.5 for the
peptide classified as binders and getting less than 2 for lytic
peptides.
(TIF)
Figure S3 Bacterial growth inhibition assay for synbody
(red), peptides DR (green) and RW (black) for A) S.
epidermidis B) E. coli O157:B7 C) B. thailandensis.
(TIF)
Table S1 MIC values for selected inhibitory peptides
for each bacterium.
(DOCX)
Table S2 Kill curve kinetic studies of S. aureus binding
peptide, inhibitory peptide, and synbody.
(DOCX)
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